Citations 1
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Hegde, Aparna , Hennon, Mark, Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Martins, Renato , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Yanagawa, Jane
Journal of the National Comprehensive Cancer Network | March 5, 2021 | Volume: 19 | Issue: 3 | Pages: 254-266
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.